Diary - News
All news Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
100% seroconversion rate achieved at Day 28 after a single-shot vaccination in a pooled analysis1 of all dose groups
Pooled analysis showed a high antibody response based on geometric mean titre
No serious adverse events or adverse events of special interest were reported up to Day 28
Saint Herblain (France), January 7, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced positive Phase 1 interim results for its Chikungunya vaccine candidate, VLA1553. The primary objective of VLA1553-101 Phase 1 study was to assess the overall safety and immunogenicity profile 28 days after a single vaccination across three dose levels.
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree